A cell viability assay showed that the ectopic expression of BRAFV600E in an NTRK1 fusion-positive pancreatic cancer cell line maintained a strong proliferation trend under LOXO-195 treatment conditions. This evidence concerns the gene NTRK1 and familial pancreatic carcinoma.